Thienothiazines
Lornoxicam 98.0+%, TCI America™
CAS: 70374-39-9 Molecular Formula: C13H10ClN3O4S2 Molecular Weight (g/mol): 371.81 MDL Number: MFCD00866163 InChI Key: WLHQHAUOOXYABV-UHFFFAOYSA-N Synonym: 6-Chloro-4-hydroxy-2-methyl-N-(2-pyridyl)-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-Dioxide PubChem CID: 54690031 ChEBI: CHEBI:31783 IUPAC Name: 6-chloro-4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-ylthieno[2,3-e]thiazine-3-carboxamide SMILES: CN1C(=C(C2=C(S1(=O)=O)C=C(S2)Cl)O)C(=O)NC3=CC=CC=N3
![(S)-6-Chloro-4-hydroxy-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine 1,1-Dioxide 98.0+%, TCI America™](https://assets.fishersci.com/TFS-Assets/CCG/Chemical-Structures/chemical-structure-cas-160982-16-1.jpg-250.jpg)
(S)-6-Chloro-4-hydroxy-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine 1,1-Dioxide 98.0+%, TCI America™
CAS: 160982-16-1 Molecular Formula: C6H6ClNO3S2 Molecular Weight (g/mol): 239.688 MDL Number: MFCD09033311 InChI Key: OFJGKGNJDCLNPM-SCSAIBSYSA-N PubChem CID: 11746721 IUPAC Name: (4S)-6-chloro-1,1-dioxo-3,4-dihydro-2H-thieno[3,2-e]thiazin-4-ol SMILES: C1C(C2=C(SC(=C2)Cl)S(=O)(=O)N1)O
Brinzolamide 98.0+%, TCI America™
CAS: 138890-62-7 Molecular Formula: C12H21N3O5S3 Molecular Weight (g/mol): 383.496 MDL Number: MFCD08067749 InChI Key: HCRKCZRJWPKOAR-JTQLQIEISA-N Synonym: (R)-4-(Ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-Dioxide PubChem CID: 68844 ChEBI: CHEBI:41212 IUPAC Name: (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide SMILES: CCNC1CN(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)CCCOC
Medchemexpress LLC Lornoxicam | 70374-39-9 | 98.7% | 1 ML
Lornoxicam is an orally active nonsteroidal anti-inflammatory drug (NSAID) that demonstrates analgesic, anti-inflammatory, antipyretic, and anticancer properties. It effectively inhibits both COX-1 and COX-2, as well as the production of NO by iNOS and the proinflammatory cytokine IL-6. This compound also inhibits tumor cell proliferation and migration and induces tumor cell apoptosis, making it suitable for research into inflammatory pain, colorectal cancer, and breast cancer.
- Orally active nonsteroidal anti-inflammatory drug (NSAID)
- Exhibits analgesic, anti-inflammatory, antipyretic, and anticancer activities
- Effectively inhibits COX-1 and COX-2
- Inhibits NO production by iNOS
- Inhibits proinflammatory cytokine IL-6
- Inhibits tumor cell proliferation and migration
- Induces tumor cell apoptosis
- Useful in inflammatory pain, colorectal cancer, and breast cancer studies
Medchemexpress LLC Brinzolamide | 138890-62-7 | 99.91% | 1 ML
Brinzolamide (AL-4862) is a highly selective carbonic anhydrase II inhibitor, demonstrating an IC50 value of 3.2 nM. It functions by reducing intraocular pressure through the inhibition of ciliary CA-II, thereby decreasing atrial fluid secretion. This compound is utilized in the topical treatment of elevated intraocular pressure in individuals diagnosed with ocular hypertension or open-angle glaucoma.
- Selective carbonic anhydrase II inhibitor
- IC50 value of 3.2 nM
- Reduces intraocular pressure
- Inhibits ciliary CA-II
- Decreases atrial fluid secretion
- Used for ocular hypertension
- Used for open-angle glaucoma
Selleck Chemical LLC Lornoxicam S2047-50mg
Lornoxicam (Chlortenoxicam) is a non-steroidal COX-1/COX-2 inhibitor used as an anti-inflammatory drug to treat pain osteoarthritis and rheumatoid arthritis
Selleck Chemical LLC Lornoxicam S2047-10mg
Lornoxicam (Chlortenoxicam) is a non-steroidal COX-1/COX-2 inhibitor used as an anti-inflammatory drug to treat pain osteoarthritis and rheumatoid arthritis
TARGETMOL CHEMICALS INC BRINZOLAMIDE 50MG
Also available in 5 mg 10 mg 25 mg 100 mg 200 mg 500 mg 1 mL 10 mM (in DMSO) and bulk. Please contact Fisher for quotes. Brinzolamide (AL-4862) is a Carbonic Anhydrase Inhibitor. The mechanism of action of brinzolamide is as a Carbonic Anhydrase Inhibitor. purity: 100%
Cayman Chemical BRINZOLAMIDE 50MG
A potent carbonic anhydrase inhibitor (IC50s = 3.19 and 45.3 nM for CAII and CAIV, respectively); selective for CAII and CAIV over CAI (IC50 = ~1,365 nM); reduces intestinal charcoal meal progression by 44% and prolongs pentobarbital sodium-induced sleep time by 35% in mice at 30 mg/kg; topical administration reduces intraocular pressure in a rabbit model of spontaneous ocular hypertension at 0.25, 0.5, and 1 mg/eye; reduces IOP in a cynomolgus monkey model of argon laser trabeculoplasty-induced ocular hypertension
Cayman Chemical BrInzolamIde 25mg
A potent carbonic anhydrase inhibitor (IC50s = 3.19 and 45.3 nM for CAII and CAIV, respectively); selective for CAII and CAIV over CAI (IC50 = ~1,365 nM); reduces intestinal charcoal meal progression by 44% and prolongs pentobarbital sodium-induced sleep time by 35% in mice at 30 mg/kg; topical administration reduces intraocular pressure in a rabbit model of spontaneous ocular hypertension at 0.25, 0.5, and 1 mg/eye; reduces IOP in a cynomolgus monkey model of argon laser trabeculoplasty-induced ocular hypertension
Cayman Chemical BrInzolamIde 100mg
A potent carbonic anhydrase inhibitor (IC50s = 3.19 and 45.3 nM for CAII and CAIV, respectively); selective for CAII and CAIV over CAI (IC50 = ~1,365 nM); reduces intestinal charcoal meal progression by 44% and prolongs pentobarbital sodium-induced sleep time by 35% in mice at 30 mg/kg; topical administration reduces intraocular pressure in a rabbit model of spontaneous ocular hypertension at 0.25, 0.5, and 1 mg/eye; reduces IOP in a cynomolgus monkey model of argon laser trabeculoplasty-induced ocular hypertension
Cayman Chemical BrInzolamIde 10mg
A potent carbonic anhydrase inhibitor (IC50s = 3.19 and 45.3 nM for CAII and CAIV, respectively); selective for CAII and CAIV over CAI (IC50 = ~1,365 nM); reduces intestinal charcoal meal progression by 44% and prolongs pentobarbital sodium-induced sleep time by 35% in mice at 30 mg/kg; topical administration reduces intraocular pressure in a rabbit model of spontaneous ocular hypertension at 0.25, 0.5, and 1 mg/eye; reduces IOP in a cynomolgus monkey model of argon laser trabeculoplasty-induced ocular hypertension
Apexbio Technology LLC Lornoxicam 70374-39-9 10mM (in 1mL DMSO)
Lornoxicam (CAS 70374-39-9) is an oxicam-class nonsteroidal anti-inflammatory drug (NSAID) that exerts its pharmacological effects primarily by potent inhibition of cyclooxygenase isoforms COX-1 and COX-2 with in vitro IC50 values of 5 nM and 8 nM respectively Studies in intact human cells and whole blood confirm its strong suppressive activity against both COX isoenzymes Additionally lornoxicam displays dose-dependent inhibition of nitric oxide formation (IC50 65 M) and reduction of IL-6 production in vitro Due to its robust COX inhibition and favorable pharmacokinetic profile lornoxicam is widely utilized as a research tool in studies investigating inflammation pain pathways and COX-mediated prostaglandin synthesis
Apexbio Technology LLC Lornoxicam 70374-39-9 200mg
Lornoxicam (CAS 70374-39-9) is an oxicam-class nonsteroidal anti-inflammatory drug (NSAID) that exerts its pharmacological effects primarily by potent inhibition of cyclooxygenase isoforms COX-1 and COX-2 with in vitro IC50 values of 5 nM and 8 nM respectively Studies in intact human cells and whole blood confirm its strong suppressive activity against both COX isoenzymes Additionally lornoxicam displays dose-dependent inhibition of nitric oxide formation (IC50 65 M) and reduction of IL-6 production in vitro Due to its robust COX inhibition and favorable pharmacokinetic profile lornoxicam is widely utilized as a research tool in studies investigating inflammation pain pathways and COX-mediated prostaglandin synthesis